U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07848945) titled 'Phase I Study of JY1001 Injection' on Sept. 17.
Brief Summary: The goal of this dose esclation study is to evaluate the safety, tolerability, and PK characteristicsafter of a single dose of JY1001 injection in healthy participants. A total of 6 cohorts are planned to be evaluated. Each cohort will enroll 8 participants to receive JY1001 or placebo in 3:1 ratio.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Pain After Surgery
Intervention:
DRUG: JY1001
Participants will receive a single dose of JY1001 (10 mg, 20 mg, 40 mg, 80 mg, 160 mg, 320 mg) via IV at Day 1
DRUG: Placebo
Participants will receive a si...